Clinical trials
Biliary Tract Diseases clinical trials
Below are recruiting biliary tract diseases clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05222971RecruitingPhase 2
Olaparib, with or without immunotherapy, for DNA-repair biliary cancer
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
SeoulAges 19 years+ - NCT07606599RecruitingPhase 3
New drug BL-M07D1 for advanced biliary tract cancer
This trial tests a new drug called BL-M07D1 against standard chemotherapy for biliary tract cancer that has spread or is locally advanced and has stopped responding to platinum-based chemotherapy. The trial is looking for patients whose cancer has a specific genetic marker to see if this new treatment works better.
Hefei, AnhuiAges 18–75 - NCT06037980RecruitingPhase 2/Phase 3
Chemotherapy before surgery for high-risk bile duct cancer
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
AnconaAges 18–75 - NCT07025174RecruitingPhase 2
Sequential anti-angiogenic therapy after immunotherapy for advanced bile duct cancer
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
Hangzhou, ZhejiangAges 18–75 - NCT06778031RecruitingPhase 2
Study of SHR-A1811 for HER2-positive bile duct cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Harbin, HeilongjiangAges 18–75 - NCT07641036RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Biliary Tract Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
Shenzhen, GuangdongAges 18 years+ - NCT07530445RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced biliary tract cancer
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted drug (lenvatinib) for biliary tract cancer that has spread or cannot be surgically removed. The goal is to slow cancer growth in patients whose cancer has progressed after one prior treatment.
GuangzhouAges 18–70 - NCT06988592Recruiting
Chemo plus immunotherapy for advanced bile duct cancer
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Duarte, CaliforniaAges 18 years+ - NCT05749900RecruitingPhase 1/Phase 2
First-line antibody, chemo, and immunotherapy for HER2 bile duct cancer
This trial studies a combination of trastuzumab (an antibody), gemcitabine and cisplatin (chemo), plus nivolumab (immunotherapy) as the first treatment for advanced HER2-positive biliary tract cancer. It may help shrink tumors and improve outcomes by targeting HER2 and boosting the immune system.
SeoulAges 19 years+ - NCT07405086RecruitingPhase 4
Morning vs. afternoon immunotherapy for advanced solid tumors
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Portland, OregonAges 18 years+ - NCT05849480RecruitingPhase 1/Phase 2
Study of CD40 treatment with CAPOX and Keytruda for bile duct cancer
This trial studies a new immune “switch” treatment called CDX-1140 combined with standard chemo (CAPOX) and Keytruda, for biliary tract cancer that can’t be cured with surgery or transplant. It’s designed for people whose cancer has progressed after first-line treatment, with the goal of improving cancer control and outcomes.
Bethesda, MarylandAges 18–120 - NCT05615818RecruitingPhase 3
Study of targeted drug choices for advanced bile duct cancers
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
BrusselsAges 18 years+ - NCT07062536RecruitingPhase 2
Comparing Two Chemo Combos for Advanced Bile Duct Cancer
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Busan, BusanAges 19–99 - NCT06202131Recruiting
Blood test for tumor DNA in gastrointestinal cancers
This trial uses a blood test (ctDNA) to look for genetic material from tumors in patients with gastrointestinal cancers. It may help doctors understand and track your cancer better.
Rome, LazioAges 18–85 - NCT06274879RecruitingPhase 2
Radiofrequency ablation for bile duct cancer
This trial tests a procedure that uses heat (radiofrequency ablation) to treat bile duct cancer that can't be removed by surgery. If you have this type of cancer and are starting standard treatment, this study wants to see if adding this heat treatment is safe and might help.
BernAges 18 years+ - NCT06849193Recruiting
Predicting treatment outcomes in advanced bile duct cancer
This study looks at how well current chemotherapy and immunotherapy work for advanced bile duct or gallbladder cancers that cannot be removed by surgery. Researchers will collect data from multiple centers to build a model that helps predict how patients may respond to treatment.
Nanjing, JiangsuAges 18 years+ - NCT07763301RecruitingPhase 1
Vaccine for advanced liver, bile duct, or pancreatic cancer
This trial is testing an investigational vaccine (YMN-136) for people with advanced liver, bile duct, or pancreatic cancer that has not responded to standard treatments or is not tolerated. The vaccine aims to help your immune system fight the cancer. It may be an option if standard treatments have failed.
Chengdu, SichuanAges 18–75 - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT07609641Recruiting
Surgery for Bile Duct Cancer: Two Surgical Approaches
This trial compares two different surgical approaches for treating bile duct cancer (cholangiocarcinoma) to see which method works better and is safer. You would undergo surgery and have your recovery and outcomes closely monitored.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+
Hear when a new Biliary Tract Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary tract diseases?
- Yes. Clin2 currently lists 109 recruiting biliary tract diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary tract diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary tract diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.